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Abstract 
 
SERUM CONCENTRATIONS OF PROTEIN 
 S100B AND THE MENSTRUAL CYCLE 
 
Jessica Elyn Morgan 
B.S., Appalachian State University 
M.S., Appalachian State University 
 
 
Chairperson:  Matthew Rogatzki 
 
 
 Protein S100B can be found in the serum of blood and is a biomarker for the blood 
brain barrier. S100B can be found in adipose tissue, skeletal muscle, and brain tissue; 
therefore, S100B concentrations can increase in the serum with excess adiposity or obesity, 
exercise, or a traumatic brain injury (TBI). In sport, S100B has been considered a possible 
indicator of sports related concussion (SRC) independent of exercise. Women tend to have 
more severe symptoms from SRC than men for a reason that has not been fully explained. 
The menstrual cycle phase and contraceptive use in women have both shown to have an 
effect on the severity of symptoms after a TBI. The goal of this study was to determine if 
protein S100B concentrations were affected by the phases of the menstrual cycle or the use of 
a contraceptive. A group of men (N=15), women taking a contraceptive (N=15), and women 
not taking a contraceptive (N=15) were recruited and all participants underwent the same 
testing protocol. Each participant came to the lab three separate times within 21-30 days 
depending on cycle length; analysis dates for men was comparable to women. The first visit 
for each participant was during the week of menses, the next visit was 10-15 days later, and 
the last visit was 3-7 days after the second. Participants were given a health history form to 
ensure inclusion criteria. Then they were asked to provide a urine sample to determine the 
phase of the menstrual cycle based off hormones in the sample. Next participants underwent a 
body composition analysis to determine body fat percentage using the BodPod. Lastly the 
 v 
participant endured a blood draw which was processed using a centrifuge to isolate the serum 
which was then stored at -80 degrees Celcius. After all samples for each participant was 
collected, an enzyme-linked immunosorbent assay (ELISA) was performed to determine 
S100B concentrations. A one-way analysis of variance (ANOVA) was used in measuring 
S100B among the different sample groups, and a repeated measures ANOVA was used to 
analyze the relationship within groups of S100B concentrations to the menstrual phases. 
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Introduction 
Serum S100B is a biomarker of blood brain barrier (BBB) disruption that has been highly 
researched in regard to traumatic brain injury (TBI) and sports-related concussion (SRC). The 
biomarker has been shown to be of higher concentration systemically after a head injury (Koh & Lee, 
2014). Concentrations of S100B can increase simply due to increased adiposity (Pham, 2010) as well 
as exercise (Hasselblatt et al., 2004; Rogatzki, 2018); however, the incidence of a concussion causes 
the increase to be of greater magnitude (Kiechle et al., 2014). Therefore, S100B can be considered 
while diagnosing TBI or SRC (Kiechle et al., 2014).  
 For reasons unknown, women tend to have worse post-concussive symptoms when compared 
to men. In a study by Delaney et al. (2002), female soccer players were found to be at greater risk of 
suffering a concussion than males; the increased risk was attributed to anatomical differences in neck 
and torso size. Post-concussive symptoms in female athletes have been associated with hormonal 
fluctuations of the menstrual cycle, suggesting that it should be taken into account while deciding 
return-to-play (Brown et al., 2015). Even contraceptive use has been examined in regard to its effects 
in recovery time from SRC symptoms in women. Women who used a form of contraception had less 
severe post-concussive symptoms than women who were not using a form of contraception 
(Gallagher et al, 2018). Men do not use contraceptives and therefore their only link to recovery time 
is the severity of post-concussive symptoms they present. In women the use of contraception can 
influence the severity of post-concussive symptoms, however contraception use itself does not 
influence recovery time (Gallagher et al, 2018). 
Research needs to be done to determine if the menstrual cycle has any effect on S100B to 
determine if it plays a role on baseline concentrations. This research would benefit future SRC and 
TBI studies. 
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Problem Statement 
The purpose of this study is to examine the variation of S100B during different phases of the 
menstrual cycle and in regards to contraceptive use. 
Hypothesis 
 We hypothesize there will be no change in S100B during the different phases of the menstrual cycle, 
however we do expect to see a difference in S100B concentrations for women who use hormonal 
contraceptives. 
Summary 
One group of men and two different groups of women, all between the ages of 18-30 will be recruited 
for this study. The two experimental groups will consist of women who may or may not be using a 
form of contraception that does not alter normal menstruation and have not had a concussion within 
the past six months. The control group will be men who have not suffered from a concussion within 
the past six months. A blood sample during the early follicular (menses), late follicular (ovulation), 
and mid-luteal phases of the menstrual phase will be obtained from the two experimental groups. The 
control group will be tested three times over a similar 28-day cycle. An enzyme-linked 
immunosorbent assay (ELISA) will be run on the blood to determine the concentration of S100B at 
each phase of the menstrual cycle. A comparison of results using a repeated-measures analysis of 
variance (RMANOVA) within groups will determine if the phases of the menstrual cycle have an 
effect on the concentration of S100B. A one-way ANOVA will also be used to determine S100B 
concentration differences among the sample population groups. 
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Literature Review 
Concussion 
 A concussion is a form of brain injury caused by an external force which effects 
pathophysiological processes of the brain (McCrory et al., 2017). When taking into account the 
number of sports-related TBI that occur each year, ranging from total loss of consciousness to those 
who seek no medical care, a total of 1.6 to 3.8 million cases have been estimated (Langlois et al., 
2006). Considering the numerous symptoms (headache, neurological deficit, amnesia, slowed 
reaction time, drowsiness, etc.) that can be unique to each individual, diagnosis of severity can be a 
complicated task (McCrory et al., 2017). TBI severity can be clinically diagnosed by intracranial 
computerized tomography (CT), focal neurological signs, post traumatic amnesia, or Glasgow Coma 
Score (GCS); most tests are for diagnosing more severe TBI even though mild is the most common 
form in clinical and sport settings (Begaz et al., 2006). In most SRCs, athletic trainers or team 
physicians are those who diagnose the concussion based on number of present symptoms to decide 
the severity of the injury to determine further analysis and return to play (Covassin et al., 2009). 
Specific guidelines are given for reporting a concussion by the National Athletic Training Association 
(NATA), but there is no standardization in how athletic training students are taught to properly 
diagnose a concussion. As a result, organizations are expected to keep up to date with new guidelines 
and teach their students how to diagnose a concussion in whatever manner they please (Covassin et 
al., 2009).  
Athletes can be reluctant to seek medical advice especially when it comes to reporting a 
concussion. Some athletes are aware of the signs and continue to compete, others may not be aware 
they have suffered from a concussion and still continue to compete. This has been shown in a study 
done by Delaney et al. (2002), where out of the 70.4% of football players who acquired at least one 
concussion within a year, only 23.4% recognized the signs of the concussion. Unfortunately, athletes 
 
 
4 
do not always realize the repercussions that follow ignorance to report a head injury. Once an 
individual has suffered from one concussion, they are more susceptible to suffer from another in the 
incidence of an additional head injury as well as post-concussive symptoms while still trying to heal 
from the previous injury (Hergenroeder et al., 2008). Athletes are the most at risk for this reason. If an 
athlete obtained a concussion in a sporting event and continued to play and had any more impacts to 
the head, they are at greater risk of suffering from a more devastating TBI as well as harsher 
symptoms. 
 
S100B  
S100B is a calcium-binding protein with an intracellular function to stimulate cell 
proliferation and migration as well as inhibit apoptosis and differentiation (Donato et al., 2009). It 
also has extracellular tendencies to bind with a receptor for advanced glycation end products (Donato 
et al., 2009). S100B has a half-life of approximately one hour which has been supported by in 
previous literature (Jeter et al., 2013; Kawata, Liu et al., 2016; Kawata, Rubin et al., 2017). S100B is 
also a BBB biomarker that has been well linked with head injuries and TBI. This means if an 
individual underwent another concussive event post one hour of the original, S100B concentrations 
would not be affected as the previous increase would have subsequently reached baseline. The 
biomarker can be found in the glial cells of the central nervous system; however, this is not the only 
place in the body it is present (Koh et al., 2014). 
Pham etal. (2010) compared different types of tissue using different testing methods such as 
ELISA, Western blot, and mass spectroscopy to support findings that S100B is expressed highest in 
brain tissue; however, they also found increased concentrations of S100B in skeletal muscle and 
adipose tissue. S100B could be a good indicator of a concussion as its concentrations do rise 
following concussion, however exercise alone can cause a rise in concentration as well (Kiechle et al., 
2014; Pham et al., 2010; Rogatzki, 2018). In higher intensity mixed with long duration exercises such 
as a marathon or a long run, S100B concentration appeared to be elevated similar to those who have 
 
 
5 
experienced a mild TBI even though no head injury had occurred (Hasselblatt et al, 2004; Rogatzki, 
2018). Independently of exercise, S100B concentrations still appear to be higher after an SRC; 
hypothetically stating there could be a threshold to determine if someone has had a concussion 
whether or not they were participating in a sport (Kiechle et al., 2014).   
As supported by previous literature, S100B is widely researched in response to concussion, 
and its increase when linked with a concussion can also be associated with prognosis and return to 
play for athletes (Graham et al., 2015; Korfias et al., 2007; Papa et al., 2015). Measuring S100B 
concentration changes in response to a function of the body, such as the menstrual cycle,  is important 
to determine if the cycle changes the concentration; this knowledge can better benefit future research 
into the biomarker and provide a stronger reasoning as to why it increases and decreases at different 
times. Research into the effects of the menstrual cycle on this biomarker has thus far been 
overlooked, and findings from this research could help shed light into the sex differences that could 
be present in the concentration of S100B in serum. For reasons that have yet to be thoroughly 
explained, women have harsher post-concussive symptoms and a longer return-to-play time than men. 
Previous explanations refer to anatomical differences (Brown et al., 2015), the possibility of 
contraceptive use (Gallagher et al., 2018), and even the menstrual cycle (Delaney et al., 2002). 
 
The Menstrual Cycle 
The menstrual cycle consists of two specific phases; the follicular phase which begins with 
the onset of menses and ends with the onset of ovulation, and the luteal phase which is approximately 
14 days in length and ends upon the first day of menses. Estrogen is secreted throughout the cycle 
with a rise in the mid-follicular and the mid-luteal phases with a subsequent fall thereafter. The phase 
of menstruation can be confirmed through biochemical analysis of estrogen and luteinizing hormone 
(LH) (Reed & Carr, 2000).  
When performing a biochemical analysis of hormones, average concentrations at each phase 
need to be taken into consideration. There appears to be a difference in estrogen secretion between 
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race according to Marsh etal. (2011) where African American women have higher concentrations of 
estrogen when compared to Caucasian women. However, both groups still show a rise at similar times 
during each phase, with African American women synthesizing an overall higher total amount of 
estrogen. Peak estrogen concentrations appear during the LH pre-ovulation surge at 200 to 500 
pg/mL, 20 to 80 pg/mL in the mid-follicular phase, and 60 to 200 pg/mL in the mid-luteal phase in 
eumenorrheic women (Carmina et al., 2009; Carmina et al., 2019). 
 There has been evidence to support that the phase of the menstrual cycle a woman is in at the 
time of a brain injury can have an effect on her recovery and post-concussive symptoms. A study 
performed on women who had suffered from a TBI showed women who obtained the injury during 
the luteal phase, experienced harsher post-concussive symptoms as well as lower quality of life 
compared to those in the follicular phase (Wunderle et al., 2014). In a study by Mihalik etal. (2009), 
non-concussed women underwent standard concussion tests in different phases of the menstrual cycle 
to determine if the phase could affect neurocognition, postural stability, or symptom status. This study 
showed any discrepancies that occurred were independent of menstrual cycle phase (Mihalik et al., 
2009). 
 
Contraceptive Use 
 Hormonal contraceptive use is always a factor for research involving women since it can 
affect blood proteins, along with behavioral and cognitive traits. Contraceptives have been shown to 
play a role in SRC recovery in that they can be protective and decrease return to play time in athletes 
as well as decrease overall symptoms (Gallagher et al., 2018). This is important, as the use of 
hormonal contraceptives can decrease an athlete’s return-to-play and can be used for future research 
for helping recover from a concussion. It has also been shown that women who are taking 
contraceptives at the time of injury tend to perform better on post-concussive and return-to-play tests, 
and return faster than those who are not on any form of contraception (Wunderle et al., 2014).  
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 The effect of hormonal contraceptives on female hormone levels is well understood, but what 
tends to get overlooked in the process is how each contraceptive can have a different effect on blood 
proteins. In a double-blinded study, four different contraceptives were given to women and a blood 
analysis was performed to test their effects on hormones as well as blood proteins. Each contraceptive 
had a different effect on the tested blood proteins (thyroxine-binding globulin, corticosteroid-binding 
globulin, and sex hormone-binding globulin), thus indicating contraceptive use alone can alter blood 
chemistry (Wiegratz et al., 2003). This study only looked at these serum-binding globulins, but the 
effect of the contraceptives used on proteins like S100B cannot be determined without further 
research. 
 
Methods 
Participants 
 Subjects were recruited in the local community by flyers, emails, and class announcements. 
Prior to analysis, all participants were asked to complete a short medical history form and research 
consent form. The sample included one group of women taking a form of contraception (N=15), a 
group of women not using a contraceptive (N=15), and one group of men (N=15) with an age ranging 
from 18-30 years. All women were required to experience a normal menstrual cycle every month and 
not yet undergone menopause. The study design was a three-group study design, women were divided 
into contraception and non-contraception users and men were control. An ELISA of S100B was 
compared during the early and late follicular phases as well as the mid-luteal phase of the menstrual 
cycle.  
Participants were excluded if they were not eumenorrheic, took a form of contraception that 
prevented menses from occurring, started taking or changed contraceptives within the past year, have 
been diagnosed with a concussion within the past six months, consumed any medication that alters 
hormones or the menstrual cycle such as steroids, antidepressants, antipsychotics, and thyroid 
medication, had a history of fainting while giving blood, had been diagnosed with endometriosis, had 
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a high percentage of body fat (higher than 40% for women and higher than 30% for men), had been 
diagnosed with hemophilia or diabetes, weighed less than 110 pounds, or if they were pregnant or had 
given birth within the last year. 
The research was conducted over the course of 12-15 weeks, following a normal menstrual 
cycle, until all participants had provided all blood and urine samples and anthropometric data required 
in each menstrual cycle phase. Only participants who completed all mandatory visits were included in 
the study. The men were tested on a similar day of the month as a woman as if to follow a menstrual 
cycle. Since men do not experience a menstrual cycle, they began the study at any time of the month 
and followed the same phase dates as the women. When any man or woman entered the lab, their 
assigned start date fell on early follicular (day 1-5), their next visit was for late follicular (day 12-14), 
and last visit for mid luteal (day 17-20).  The medications taken by contraceptive participants were a 
hormonal contraceptive that still allowed for normal menses to occur. Medication name and dosage 
were provided on the medical background and there were no changes to type during the testing 
period.  
Participants who fit the inclusion criteria were asked each visit to abstain from physical 
activity 12-hours prior to arriving in the lab and underwent the following procedures: a body 
composition test was performed using a COSMED BodPod (Life Measurement, Inc; Rome, Italy) to 
determine differences between men and women. Women underwent ovulation testing to confirm their 
phase of the menstrual cycle. The participants then underwent a standard venipuncture to a prominent 
vein in the antecubital space. 
 
Ovulation Testing  
 Once a woman was recruited and was properly consented, she informed the researcher of the 
first day of menses so the early follicular stage data could be collected. When the participant finished 
with menses, she contacted the researcher once more so she could take an ovulation test to pinpoint 
the exact days of ovulation. After those days were documented the participant came back to the lab 
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during a given time frame so the late follicular measurement could be obtained. Lastly, the mid-luteal 
phase was calculated based on the ovulation measurement and the last-first day of menses.  
The phases were set apart from another by using an ovulation detection monitor (Clearblue 
Fertility Monitor, Touch Screen, 1 Count; Bedford, United Kingdom). This monitor used a urine 
sample to obtain LH and estrogen concentrations during a woman’s cycle to track the 36-hour peak 
ovulation (Fertility Monitor with Touch Screen, 2019). Women came in during the calculated time 
based off their cycle length to determine when the peak ovulation was in order to give the late 
follicular measurement. If the calculated time was not the appropriate peak then they came in 
consistently until they reached peak ovulation. 
 
Body Composition 
 When participants were enrolled in the study, they underwent a body composition 
measurement through COSMED BodPod (Life Measurement, Inc; Rome, Italy) to estimate body 
weight and composition, volume, density, body fat mass, and fat-free mass (Cosmed, 2019). The 
participants were instructed to wear proper clothing required for the measurement before each visit. 
Each participant went through standard BodPod protocol with each visit to control for any weight loss 
or gain that may have occurred during the study or due to the menstrual cycle.  
 
Blood Processing  
One serum-separating tube (SST) was filled with four milliliters of venous blood using a 
standard venipuncture procedure, inverted 8 times to mix the blood with the clotting factor, and then 
set aside for at least 30 minutes at room temperature, but no longer than one hour for proper 
coagulation. The blood was then be centrifuged at room temperature for five minutes at 5,600 
revolutions per minute to separate the serum. The serum was then removed and stored at -80 degrees 
Celsius until S100B was analyzed. This procedure was performed three times per participant, one for 
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each tested phase of the menstrual cycle. Once all samples were taken, S100B was tested against the 
phases of the menstrual cycle to determine its concentration throughout the cycle.  
 
Medical History 
 Prior to blood draw, the participant took part in a medical questionnaire. They were asked 
age, weight, and questions relating to the exclusion criteria to be sure they fit in the study. The rest of 
the questions were used to determine the use of contraceptive and check for normal menstruation. 
These questions asked if they experience normal, monthly menstrual cycles for at least three 
consecutive months, if they use a form of contraception and if so they were required to list the 
specified type, the length of their average period, etc. All participants were given a code (e.g., 
MCM01, MCFC02, MCFN03) to impair identifiability and preserve their identity throughout the 
experiment.   
 
Extended Methods 
Recruitment and Scheduling 
 After a subject was recruited in the Appalachian State and/or Boone community they were 
informed to either provide an email to be reached or were requested to email the principal 
investigator. The following email was then sent to potential subjects to better educate them on what 
would be asked of them before agreeing to consent. 
Dear [PARTICIPANT NAME], 
Thank you for showing interest in my research, before I confirm schedules with you I wanted 
to give you a bit more detail as to what would be asked of you and what to expect. Please 
read the following and if you have any questions about the procedures, please do not hesitate 
to ask. 
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First you will come in and we will have you complete a health history and sign an informed 
consent. Next we will take a urine sample to test for some hormones in your urine. We will 
collect your height and weight, then take you to a machine called BodPod that will test your 
body composition. Lastly, we will perform a blood draw of 4 mL (about the size of an index 
finger) and that will be the end of your visit. You will need to attend 3 visits and we will 
schedule your next upcoming visit in the lab, but they will all need to be within a 28-day time 
frame. 
When you come to the lab you need to be fasting so no food and only water for 8 hours prior. 
You cannot have exercised within 12 hours of your visit. You also need to come with either a 
change of clothes or wearing somewhere under your clothes tight clothing. The body 
composition test recommends wearing a tight bathing suit, but spandex or tight shorts are fine 
as well. We will provide a swim cap. 
The following questions will be on the health history form when you come into the lab as 
well, but I need to confirm them before I have you come in for testing. You can simply reply 
no all or yes to any that apply, if the question does not apply to you then simply answer N/A. 
After I get the email confirmation, we can schedule a time for you to come into the lab. 
Again, thank you so much for showing interest and if you have any questions about anything 
please feel free to ask! 
Are you taking birth control? If so is it a type that allows you to have a normal period each 
month? (Ex no IUD) 
If you are on birth control have you been on the same kind for at least 6 months? 
Have you had a concussion within the past 6 months? 
Do you consume any form of steroids, antidepressants, antipsychotics, and/or thyroid 
medication? 
Do you have a history of fainting while giving blood? 
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The point of this email was to inform potential subjects of what would be asked of them and 
how to properly prepare before entering the lab. The questions were also inserted in the email to 
ensure that participants fell within the inclusion criteria of the project and could be scheduled into lab 
accordingly. For men, a time was scheduled immediately that worked best for them. When women 
responded to the questions, the following question was asked: “When do you anticipate your next 
period to start?” Based on the answer to this question, the lab date was scheduled within 5 days of the 
initial date to start. 
Before a time was confirmed that worked with the investigator as well as the participant, a 
reservation was made on the body composition lab calendar to ensure no other researchers had 
already reserved the lab during that time frame. Once all schedules matched and an agreed upon time 
could be scheduled, a confirmation email through google calendar was sent to the subject as well as 
any lab assistants that may help with data collection. When google calendar confirmation emails were 
sent, there was an option to agree to the appointment or decline so the investigator could be aware of 
exactly who would help with each data collection. Lastly, the day before data collection an email was 
sent to the participant to ensure they prepared to come to lab properly and one last time to confirm the 
time they needed to be at the lab. This email was simply stating:  
Hello [NAME OF PARTICIPANT], 
Thank you again for agreeing to be a part of my study. Please be sure to wear a tight bathing 
suit or tight clothing, do not eat anything for 8 hours before entering the lab, and try to enter 
the lab ready to use the bathroom. Again, let me know if you have any questions and feel free 
to text if you need help getting into the building or finding the body composition lab (room 
127) [PHONE NUMBER]. 
This was important as people would forget to fast, forget to bring or wear proper clothing, and most 
commonly people would urinate prior coming to lab rendering them unable to provide a urine sample. 
If they were unable to provide a sample when they first entered the lab, it was done at the end of the 
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blood draw and body composition test. In order to maintain consistency, the urine sample should be 
collected before the body composition analysis. 
 
Preparation for Participant 
On the day a participant was expected in lab, the researcher would get to the body 
composition lab 1.5 to 2 hours early to properly calibrate equipment and ensure it was working 
properly. When entering the lab, the BodPod was turned on by flipping the green switch on the white 
box at the bottom of the cart connected with the BodPod so a light turned on, similar to a surge 
protector. The BodPod then made a clicking noise to ensure it had been turned on. Next, the computer 
accompanying the cart was turned on by pressing the power button on the computer box that lays 
vertically on the second shelf of the cart. A small light came on next to that button and the monitor 
showed a windows icon to ensure the computer had turned on. Occasionally the computer was 
forcefully turned off in which case the monitor indicated to start windows normally. When this would 
happen the instructions on the screen were followed. There were also times that a screen would 
appear testing the communication between the BodPod and the computer itself, once communication 
was confirmed “Okay” was clicked.  
Once the desktop view was available, the icon with a picture of the egg-shaped BodPod was 
clicked, the caption was either body composition or BodPod. Once the program was opened, a login 
screen appeared requiring a username “VBASL” and “Cardiac1” as the password. The username and 
password were confirmed with the instruction paper under the keyboard of the cart. After logging on, 
the “QC” on the left side of the screen was located and “Warm-Up” was clicked. A screen appeared 
asking if a warm-up was to be initiated at a certain time and date; there was also an option “start 
warm-up now” and the instructions indicated on the screen were followed, it was ensured the volume 
canister was left sitting on the seat of the BodPod before beginning the warm-up. The volume canister 
should always be left inside the BodPod for safe keeping, if it was not present there, it was likely 
located next to the BodPod. Once the warm-up was initiated, the BodPod performed five volume 
 
 
14 
measurements, this warm-up could take up to one hour. The volumes measured by the BodPod did 
not always match that of the canister which was the reason for the calibration upon the completion of 
the warm-up; the importance of the warm-up was to indicate that the standard deviation was low 
(generally lower than 5, a negative occasionally happened as well and was nothing to worry about) 
between each measurement. The computer software indicated whether or not the standard deviation 
was too high and determine whether another warm-up was to be initiated. If the warm-up was 
considered successful, the calibration process then began. If there is an indication the warm-up was 
unsuccessful, reach out to the faculty in charge of the body composition lab (Dr. Marco Meucci but 
subject to change) for further instruction. 
In some instances, the warm-up was initiated, and a window appeared indicating the BodPod 
and computer were not linked or the computer could not find the BodPod. In this case, the BodPod 
program was closed out on the screen and the program was re-entered. Occasionally that was all that 
was needed, in other instances the entire mechanism was turned off and back on via the green switch. 
This was only performed as a last resort to complete the connection. If all programs opened again and 
the issue was still prevalent, the faculty representative (Dr. Marco Meucci but subject to change) of 
the body composition lab was alerted to determine if they could assist with the issue. As a last resort, 
if the faculty representative is not available, then a COSMED representative could be contacted 
through customer service for further assistance. There should be a booklet on the bottom of the cart 
with a number for customer service, if it is missing or not able to be found a tollfree number can be 
called (+1 800-426-3763). 
When the warm-up was finished, the calibration process began in the “QC” menu. Each of 
the following tests were completed: “Analyze Hardware,” “Scale Check,” “Autorun,” and “Volume.” 
Some tests addressed the calibration had been completed within the past two weeks and was not 
necessary; however, as good practice, and to ensure each test’s similarity, the full calibration was run 
for each before every data collection. In each of tests, the screen prompted the exact processes that 
needed to be done for each procedure; the instructions were followed accordingly – “open BodPod 
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door,” “close BodPod door,” “place calibrated weights on the scale,” “remove weights from the 
scale,” “place cylinder inside BodPod,” “remove cylinder from BodPod.” The calibrated weights, 
gold in color and weighing ten kilograms each, were both placed in the middle of the scale for the 
calibration. The weights were found sitting either right in front of the BodPod labeled scale or beside 
the BodPod itself. When doing each of these tasks it was ensured the cylinder was not dropped or 
harmed as it has been calibrated to the nearest thousandth and any dents could change that number. It 
was also ensured the BodPod scale was being used and not any others present in the body 
composition lab. The calibrated weights were stored beside the BodPod, as well as the cylinder inside 
the BodPod when it was not being used.  
Once the BodPod calibration was completed, necessary items from the biochemistry lab for 
testing were acquired: urine sample cup stored on the shelves at the back of the lab just over the large 
centrifuge, a urine test stick, and the travel phlebotomy bag. Inside the bag were nitrile gloves, 
tourniquets, 21-guage butterfly needles, vacutainer adapters, red-top vaccutainers, band-aids, alcohol 
swabs, gauze pads, and a stress ball. Lastly, an informed consent and a health history form were 
acquired if it was the subject’s first attendance. The phlebotomy bag and contents were taken to the 
phlebotomy lab and the rest was taken to the body composition lab where the informed consent took 
place.  
 
Data Collection with Participant 
After consent was signed and the health history form was completed, the Body Composition 
tab of the BodPod screen was selected and the required information was filled in – Name (subject 
ID), date of birth, gender, ethnicity (general pop or African American), height (in centimeters to the 
tenth decimal). The height measurement was taken in the body composition lab using the white 
stadiometer, and the participant did not have on shoes or socks. The participant was then instructed to 
provide a urine sample and shown the location of the restrooms. Not a lot of urine was required for 
analysis; however, if a sample was unable to be produced at the beginning of analysis, the sample was 
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taken at the end of all measurements. During this time, and after all data was entered, the next screen 
was prompted and “predicted thoracic measure” was chosen. Another simple calibration was required 
before starting the measurements. Once the subject re-entered the body composition lab, they were 
asked to change into their approved clothing, removed all jewelry, and placed the swim cap on their 
head to cover as much hair as possible. The screen then prompted to have the participant stand on the 
BodPod scale to measure body mass. 
When prompted, the cylinder was removed and the participant was asked to enter the 
BodPod. The participant sat relaxed with knees pointed forward, feet placed flat on the ground if 
possible, hands placed on legs and fingers fanned out, sitting straight and looking forward. The 
procedure was then explained to the participant – “there will be two separate tests, and each will take 
20 to 30 seconds long; there will be several ‘washy sounding’ noises during the test, but remain as 
still as possible and remember to breathe normally.” Between each test there was a prompt to open 
the door. This was to control for body heat that would get trapped inside the BodPod during each 
measurement, ensuring the temperature was the same between measurements (Shaw & Kerr, 2018). 
Occasionally the machine prompted for a third test which was required if the standard deviation 
between tests was too large. In this case, the participant was not to leave the BodPod until prompted 
to do so.  
After the participant exited the BodPod, the swim cap was removed and they changed back 
into their clothing. They were then escorted to the phlebotomy lab and instructed to sit in one of the 
phlebotomy chairs. At this time the standard venipuncture occurred, 4 mL of blood was obtained, and 
a timer was set for 45 minutes to ensure proper clotting of the blood. The next visit for the participant 
to enter the lab was scheduled based on the time of their menstrual cycle. If it was their first visit, the 
next was scheduled within ten to fifteen days to obtain the late follicular phase. If it was their second 
visit, the next visit was scheduled within four to six days. If the women had knowledge of the phases 
of their cycle, they were scheduled accordingly. Some women started menstruating earlier than 
expected; if they had already undergone the first two measures and the last measure was missed, it 
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was then captured the following month a few days before they menstruated again. This was measured 
by approximating the length of the previous menstrual cycle they endured to see how long the cycle 
lasted (time elapsed between the last day of menstruation and the first day of menstruation). By using 
this information, the best day for measuring the mid luteal phase for the following month was 
calculated to give at least a three-day buffer before the next estimated menstruation would begin to 
ensure the measurement was captured.  
After the participant exited the lab, the urine was tested to measure ovulation in a measure of 
either low, high, or peak fertility using a Clearblue fertility monitor. The Clearblue Fertility Monitor 
was a good measure of LH hormone and estrogen; however, it was made for one individual to use 
over the course of their own menstrual cycle and has not been shown to be effective in determining 
the concentration of these hormones in multiple individuals. For this study, a single use ovulation 
monitor would be more effective to give a more accurate representation of each menstrual cycle 
phase. The ClearBlue Advanced Ovulation tests would be a better alternative as they provide more 
individualized and a better indicator of both hormones for each participant.  
After the 45-minute timer ended, the blood was centrifuged using a StatSpin Express 3 
portable centrifuge (Beckman Coulter, Inc., Brea, CA) for five minutes at 5,600 revolutions per 
minute (2,685 relative centrifugal force) to separate the serum from the red blood cells. The 
centrifuge was found in the Biochemistry Laboraotry on Dr. Rogatzki’s lab bench in a box labeled 
“Rogatzki.” The serum was then pipetted and transferred to a cryotube which was found in the first 
drawer of Rogatzki’s lab bench. A cryobox was obtained from the far-right corner of the lab on the 
top shelves, many of them have been recycled so labeling them with a sharpie is necessary to not get 
mistaken with other experiments. The samples were then taken to the freezer closest to the window in 
the freezer room and in the top left storage box in that freezer; samples were frozen at -80 °C until 
analysis of all samples could occur. The leftover vaccutainer tube and blood inside was then disposed 
of in biohazardous waste. 
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Running the ELISA 
 After 45 participants were recruited and all samples were collected, four ELISA testing kits 
were ordered allowing each sample to be run in duplicate. For S100B the preferred retailer was 
millapore sigma (catalog number: EZHS100B-33K); however, due to price, other retailers can be 
chosen as long as they have good rating from previous literature. All samples were taken from the 
freezer and stored overnight in the refrigerator to allow them to thaw properly. On the day of analysis, 
the samples were removed from the refrigerator and incubated at room temperature for at least one 
hour before running the samples. The storage procedure of the ELISA kits was read and properly 
followed until date of analysis. The kit also indicated times of incubation in different temperatures 
before running samples.  
 In the kits there was a standard, in some cases the standards are prepared, however in other 
instances a serial dilution was required to create standards using the sample diluent. In the 96 well 
plate, each sample (including standards) was run in duplicate; meaning one sample took up two wells 
so each column of sample had another column exactly the same next to it. The sample diluent was not 
used on the samples, since serum S100B levels are generally within the range of the standard curve. 
Before the tip was inserted into the sample, the sample was vortexed to allow any proteins that may 
be at the bottom of the tube to be equally present throughout the serum. To save pipet tips, the wet tip 
method was used when filling the wells with sample. When this method was performed, some of the 
sample was drawn into the micropipette then pushed back into the sample container so the tip was 
considered wet After being vortexed and wetting the tip, the sample was inserted into both wells. The 
tip did not touch the bottom of the well as doing so would have scratched the surface and risked 
detaching the antibody. To ensure the location of the samples for later analysis, when a sample was 
put into a well the location was noted; an example would be A1 and B1 were NCEFF01. This 
technique was followed every time a sample was added into a well. 
The amount of sample added to the wells, incubation times, washing, creating the buffer, and 
any other information regarding the testing kit was found in the protocol form of the kit and was 
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thoroughly reviewed and followed to ensure the integrity of the assay. When the analysis was 
complete and the stop solution was set, the absorbance of the samples was read by putting the plate in 
the Eon spectrophotometer (BioTek Instruments, Inc., Winooski, VT USA) located in the sensitive 
equipment room within the Biochemistry laboratory at the wavelength required by the instructions. 
Before exiting the program, all information regarding the samples was exported to an external drive 
on Microsoft Excel. Using Excel, the standard curve, intra-assay coefficient of variation, and inter-
assay coefficient of variation were calculated. Intra-assay coefficient of variation should be less than 
10% and inter-assay coefficient of variation should be less than 15%. After the concentrations of 
S100B for each sample were determined they were transferred to SPSS for statistical analysis. 
 
Millipore Sigma ELISA Instructions 
The kit in full was stored at 2-8 o C until the date of use, the day before testing the samples 
were removed from -80 o C and moved to 2-8 o C to allow time to thaw. On day of the assay the 
standards provided by the kit were reconstituted with 0.5mL of distilled or de-ionized water. After 6 
tubes were labeled 1 to 6, 200 L of assay buffer was added to each. Starting with tube 6, 100 L of 
the reconstituted standard was added and mixed well; next 100 L was taken from tube 6 and added 
to tube 5 then mixed well, then 100 L from tube 5 was transferred to tube 4, 100 L from tube 4 to 
tube 3, 100 L from tube 3 to tube 2, and lastly 100 L from tube 2 to tube 1 and all were mixed well 
between transfers. Next the lyophilized quality control (QC) vials were both reconstituted with 0.50 
mL of distilled or deionized water and mixed until they were fully hydrated. 
The HRP wash buffer was created by adding all contents of the concentrated form into 900 
mL of deionized water. The 96-well plate was then be washed 3 times with 300 L of wash buffer 
with an immediate wash/decant cycle. When the sample was decanted, it was gently tapped on an 
absorbent towel to remove the fluid from the wells. Next 50 L of the reconstituted standard, 50 L 
from tubes 6 through 1, 50 L of assay buffer, and 50 L of QC 1 and 2 was added in duplicate to the 
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wells on the 96-well plate. Next 50 L of the samples was added to the wells in duplicate after 
performing a vortex and wet tip procedure for each sample. Once the plate was full of sample and 
standards it was covered with a plate sealer and incubated at room temperature (approximately 25 °C) 
for two hours on an orbital plate shaker set to rotate around 500 to 600 rpm or moderate speed.  
The plate sealer was then removed and all solutions were decanted, tapping gently on an 
absorbent towel and removing the samples from the wells. A similar wash cycle as before was 
performed, 300 L of wash buffer was added to each well then immediately decanted and this was 
done 5 times. After a full wash cycle, 100 L of detection antibody was added to each well, the plate 
was then recovered and incubated at room temperature for an hour and a half on an orbital shaker set 
to rotate around 500 to 600 rpm or moderate speed. After incubation, the solution was decanted and 
the wells were washed again the same as before – 300 L of wash buffer with an immediate 
wash/decant cycle for 5 cycles. The last wash cycle was decanted and 100 L of substrate solution 
was added to each well, then sealed and set on the shaker plate for 25 minutes. A blue color formed in 
the standard wells and the intensity of color was proportional to the increase in concentration. These 
colors were monitored and taken off when the color developed accordingly, they were carefully 
monitored to ensure they were not incubated for too little or too long of time. The seal was then 
removed and 100 L of stop solution was added immediately, the plate was shaken by hand gently to 
ensure proper mixing. Upon addition of stop solution the wells turned from blue to yellow. The plate 
was then placed in the spectrophotometer and read at an absorbance of 450 nm and 590 nm within 5 
minutes and the absorbance was recorded in units.  
All the standards were entered into a sigmoidal 4-parameter logistic regression equation to 
determine the concentration of all other samples. Both QCs were considered accepted when within 
the calculated range of2.7 pg·mL-1 to 2000 pg·mL-1. The intra-assay coefficient was calculated to 
determine the accuracy of the test and remained below 10% using the mean and standard deviation 
between the duplicate of each sample.  
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Calculating Results 
 Serum S100B concentration during the mid-luteal and follicular phases was analyzed with an 
ELISA kit using a 4-parameter logistic regression equation. Estrogen and LH were also analyzed via 
the ovulation stick to confirm the menstrual phase of each participant. A RMANOVA was used to 
analyze the relationship within groups of S100B concentrations to the menstrual phases. A one-way 
ANOVA was used in measuring S100B among the different sample groups. An RMANOVA was 
also run for anthropometric measures (height, weight, and body composition) to ensure there was no 
change within the menstrual cycle groups; there was also a one-way ANOVA performed to confirm 
no differences of anthropometric measures among the different sample groups. We expected to see no 
change in S100B concentrations in either the mid-luteal or the follicular phases, however we did 
expect to see a change in S100B based on contraceptive use. We planned to see a decrease in estrogen 
in the late-follicular phase and an increase in the early-follicular and mid-luteal phases for 
confirmation of the menstrual cycle phase.  
 
Reflection 
 We were unable to finish this study; however, some subjects were recruited, and we were still 
able to perform some of the tests. Keeping in mind this was a thesis research project, we did not have 
all the time and money to provide all the resources we would have liked which was the main reason 
some methods were chosen over others. Measuring hormone concentrations in the blood samples to 
confirm the phase of the menstrual cycle was our original plan, but the ELISA kits are very 
expensive, and our funds were limited. This would be a better way to determine the phase of the 
menstrual cycle, but we used the ovulation test with three values as a substitute. It was still an 
acceptable estimation and gave a general answer to give us an estimated time frame; however, it is 
not as accurate at determining menstrual cycle phase as ELISAs would be. 
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 We also used the BodPod to measure body composition. As this is a good and accurate 
measure compared to other options, the dual-energy X-ray absorptiometry (DEXA) scan gives a 
precise picture of where the fat is located as well as bone mineral density, along with all the other 
values that are not analyzed with a BodPod. Since the DEXA provides bone mineral density and a 
visual of fat distribution, differences among sexes in these categories could better be determined. 
Matching participants would be another way to improve the methods which could be done by 
matching age, height, weight, fat distribution, and activity level. The reason we did not use the DEXA 
scan on participants was due to the radiation expose each participant would have endured over the 
three visits, but in future studies this could be an alternate route to take from the BodPod.  
 The menstrual cycle has a constant flow and a constant change in hormones throughout the 
cycle, and each woman is different on how long the changes can last. Instead of doing only three 
blood draws over the course of the cycle and attempting to hit the exact 36-hour mark of ovulation, 
we would prefer to take a blood draw every day from each individual to see how their cycle in whole 
effects S100B. This would also allow for us to determine if there is a correlation between 
estrogen/progesterone fluctuations and S100B levels. 
 One thing that we thought was important to keep in the study was allowing participants to 
reflect on their lives since the last time we saw them. For example, some participants would explain 
they had the flu, they may have changed their diet, they changed their exercise plan. These factors 
were important to note since they could potentially have an effect on S100B.   
 I think this study was well performed with the few participants that were completely tested 
through. I feel that the only change I would make to the study would by using another protein or even 
multiple proteins to test for in serum and see if contraceptive use or the menstrual cycle affects any of 
them. The point of this research was to see how S100B was affected by something most female 
athletes endure. If the concentrations of S100B rise or fall during certain points of the menstrual cycle 
or due to a woman taking a contraceptive, it is a variable that future researchers need in order to 
diagnose a female with a concussion using a biomarker such as S100B.  
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Appendix 1. Summary 
 
• Email participants to determine which are compatible with inclusion criteria  
• Schedule an appointment for the participant to come into lab and send a follow up email the 
day before to remind the participant of how to enter the lab. 
• Enter lab at least an hour and a half early to ensure proper warm-up and calibration of 
BodPod 
• Give informed consent and health history form 
• Obtain height measurement then give the participant urine cup and escort to restrooms, while 
they use the restroom run the calibration on the BodPod 
• Upon return, allow the participant to change behind the curtain in the body composition lab 
then take weight using BodPod scale, and once instructed by the computer have the 
participant enter the BodPod with swim cap, proper clothing, and no jewelry 
• Follow instructions and take body composition. When finished print results and label with 
code for that day so all body composition results can be analyzed later 
• After body composition allow participant to change back into the clothes they wore to the lab 
• Take participant to phlebotomy lab and perform blood draw using proper equipment and 
disposal methods. Set a timer for 45 minutes to allow coagulation of blood. 
• Schedule the next visit for the participant to come to the lab 
• Analyze urine sample with fertility stick 
• After timer ends, spin and separate blood then transfer to cryotube to be stored in the freezer 
at -80 degrees Celsius 
• On the day for running ELISAs, be sure to follow instructions from the kit to ensure samples 
and kit is stored and thawed properly 
• Use a wet-tip method and vortex the samples before running a duplicate assay for each 
sample and be sure to record each sample location 
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• Be sure to add standards from the kit accordingly and follow all other instructions from the 
assay kit. 
• Enter all samples and locations into excel after analysis to determine concentration of S100B 
• Calculate intra-assay and inter-assay coefficients of variation 
• Use one-way ANOVA to compare data among groups (contraceptive vs. non-contraceptive 
vs. men) and a RMANOVA to compare within the phases of the cycle (early follicular, late 
follicular, and midluteal) 
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